公开(公告)号：US20130143802A1

公开(公告)日：2013-06-06

申请号：US13544595

申请日：2012-07-09

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: A61K38/39

CPC classification number: A61K38/26 ,  A61K38/00 ,  A61K38/162 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/1796 ,  A61K38/212 ,  A61K38/28 ,  A61K38/39 ,  A61K38/443 ,  A61K38/4873 ,  A61K47/6435 ,  C07K14/78 ,  C07K2319/01

Abstract: Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life. etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs.

Abstract translation: 包含包含弹性蛋白样肽（ELP）和肽活性治疗剂的融合蛋白（FP）的治疗组合物，以及制备和使用这些组合物和融合蛋白的方法。 这种类型的治疗组合物相对于单独的肽活性治疗剂使得能够实现肽活性治疗剂的功效得到改善。 肽活性治疗剂在治疗组合物中的增强的功效可以包括改善的溶解度，生物利用度，生物不可用性，半衰期。 等等，与含有相同肽活性治疗剂的相关组合物相比，没有相关的ELP。

公开(公告)号：US20130079277A1

公开(公告)日：2013-03-28

申请号：US13445979

申请日：2012-04-13

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: C07K19/00

CPC classification number: A61K38/28 ,  A61K38/16 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/4846 ,  A61K45/06 ,  A61K47/6435 ,  A61K47/65 ,  C07K14/575 ,  C07K14/605 ,  C07K14/78 ,  C07K19/00 ,  C07K2319/31

Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Abstract translation: 本发明提供治疗剂和包含弹性蛋白样肽（ELP）和治疗性蛋白质的组合物。 在一些实施方案中，治疗性蛋白质是GLP-1受体激动剂，胰岛素或因子VII / VIIa，包括功能类似物。 本发明还提供编码多核苷酸，以及制备和使用治疗剂的方法。 治疗剂与其作为治疗剂的用途有关，其中尤其包括身体的半衰期，清除和/或持久性中的一种或多种，​​溶解度和生物利用度。

公开(公告)号：US20130005664A1

公开(公告)日：2013-01-03

申请号：US13612126

申请日：2012-09-12

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: A61K38/16 ,  A61P35/00

CPC classification number: C07K14/61 ,  A61K38/00 ,  A61K38/2278 ,  A61K38/28 ,  A61K38/4846 ,  A61K45/06 ,  A61K47/64 ,  A61K47/6435 ,  A61K47/645 ,  C07K14/52 ,  C07K14/605 ,  C07K14/62 ,  C07K14/71 ,  C07K14/745 ,  C07K14/78 ,  C07K2319/31 ,  A61K2300/00

Abstract: The present invention provides therapeutic agents and compositions comprising elastic peptides and therapeutic proteins. Such peptides exhibit a flexible, extended conformation. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist (e.g., GLP-1, exendin), insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

公开(公告)号：US08178495B2

公开(公告)日：2012-05-15

申请号：US12493912

申请日：2009-06-29

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: A61K38/26 ,  A61K38/17 ,  C07H21/04

CPC classification number: A61K38/28 ,  A61K38/16 ,  A61K38/2278 ,  A61K38/26 ,  A61K38/4846 ,  A61K45/06 ,  A61K47/6435 ,  A61K47/65 ,  C07K14/575 ,  C07K14/605 ,  C07K14/78 ,  C07K19/00 ,  C07K2319/31

Abstract: The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

Abstract translation: 本发明提供治疗剂和包含弹性蛋白样肽（ELP）和治疗性蛋白质的组合物。 在一些实施方案中，治疗性蛋白质是GLP-1受体激动剂，胰岛素或因子VII / VIIa，包括功能类似物。 本发明还提供编码多核苷酸，以及制备和使用治疗剂的方法。 治疗剂与其作为治疗剂的用途有关，其中尤其包括身体的半衰期，清除和/或持久性中的一种或多种，​​溶解度和生物利用度。

公开(公告)号：US20110039776A1

公开(公告)日：2011-02-17

申请号：US12440294

申请日：2007-09-06

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: A61K38/26

CPC classification number: A61K38/26 ,  A61K38/00 ,  A61K38/162 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/1796 ,  A61K38/212 ,  A61K38/28 ,  A61K38/39 ,  A61K38/443 ,  A61K38/4873 ,  A61K47/6435 ,  C07K14/78 ,  C07K2319/01

Abstract: Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion proteins. Therapeutic compositions of such type enable improved efficacy of the peptide active therapeutic agent to be achieved, in relation to the peptide active therapeutic agent alone. Enhanced efficacy of the peptide active therapeutic agent in the therapeutic composition may include improved solubility, bioavailability, bio-unavailability, half-life, etc., as compared to corresponding compositions containing the same peptide active therapeutic agent without associated ELPs.

Abstract translation: 包含包含弹性蛋白样肽（ELP）和肽活性治疗剂的融合蛋白（FP）的治疗组合物，以及制备和使用这些组合物和融合蛋白的方法。 这种类型的治疗组合物相对于单独的肽活性治疗剂使得能够实现肽活性治疗剂的功效得到改善。 与含有相同肽活性治疗剂的相关组合物相比，治疗组合物中增强的功效可包括提高的溶解度，生物利用度，生物不可用性，半衰期等。

公开(公告)号：US20090004104A1

公开(公告)日：2009-01-01

申请号：US12158190

申请日：2006-12-20

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: A61K51/08 ,  A61K47/48 ,  A61K49/00 ,  A61K38/21 ,  A61K39/44 ,  A61K38/16 ,  A61K31/70 ,  A61K31/711 ,  A61K31/704 ,  A61K31/337 ,  A61K33/24 ,  A61K31/075 ,  A61K103/34 ,  A61K31/7105

CPC classification number: C07K14/78 ,  A61K38/193 ,  A61K38/21 ,  A61K47/6435 ,  A61K49/085 ,  A61K49/14 ,  C07K2319/00

Abstract: Provided herein are methods of enhancing in vivo efficacy of an active agent, comprising: administering to a subject an active agent that is coupled to a bioelastic polymer or elastin-like peptide, wherein the in vivo efficacy of the active agent is enhanced as compared to the same active agent when administered to the subject not coupled to (or not associated with) a bioelastic polymer or ELP.

Abstract translation: 本文提供增强活性剂的体内功效的方法，其包括：向受试者施用与生物弹性聚合物或弹性蛋白样肽偶联的活性剂，其中活性剂的体内功效与 当向受试者施用不与生物弹性聚合物或ELP（或不结合）生物弹性聚合物或ELP时相同的活性剂。

公开(公告)号：US20070072220A1

公开(公告)日：2007-03-29

申请号：US11521651

申请日：2006-09-15

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: C12Q1/68

CPC classification number: C12Q1/682 ,  B01J19/0046 ,  B01J2219/00432 ,  B01J2219/00596 ,  B01J2219/00605 ,  B01J2219/00608 ,  B01J2219/0061 ,  B01J2219/00612 ,  B01J2219/00626 ,  B01J2219/00628 ,  B01J2219/0063 ,  B01J2219/00635 ,  B01J2219/00637 ,  B01J2219/00659 ,  B01J2219/00677 ,  B01J2219/00722 ,  B01J2219/00725 ,  B01J2219/0074 ,  B82Y15/00 ,  B82Y30/00 ,  C12Q1/6837 ,  C40B50/18 ,  G01N33/5302 ,  G01N33/54353 ,  G01N33/54393 ,  C12Q2525/313 ,  C12Q2521/131

Abstract: An article such as a biosensor having a nonfouling surface thereon is described. The article comprises: (a) a substrate having a surface portion; (b) a linking layer on the surface portion; (c) a polymer layer comprising brush molecules formed on the linking layer; and (d) optionally but preferably, a first member of a specific binding pair (e.g., a protein, peptide, antibody, nucleic acid, etc.) coupled to the brush molecules. The polymer layer is preferably formed by the process of surface-initiated polymerization (SIP) of monomeric units thereon. Preferably, each of the monomeric units comprises a monomer (for example, a vinyl monomer) core group having at least one protein-resistant head group coupled thereto, to thereby form the brush molecule on the surface portion. Methods of using the articles are also described.

Abstract translation: 描述了诸如其上具有非结垢表面的生物传感器的物品。 该制品包括：（a）具有表面部分的基底; （b）表面部分上的连接层; （c）包含在所述连接层上形成的刷分子的聚合物层; 和（d）任选但优选地，偶联到刷分子的特异性结合对（例如蛋白质，肽，抗体，核酸等）的第一成员。 聚合物层优选通过其上单体单元的表面引发聚合（SIP）的方法形成。 优选地，每个单体单元包含具有至少一个与其结合的蛋白质抗性头基团的单体（例如，乙烯基单体）核心基团，从而在表面部分上形成刷分子。 还描述了使用制品的方法。

公开(公告)号：US07129096B2

公开(公告)日：2006-10-31

申请号：US10315149

申请日：2002-12-10

Applicant: Ashutosh Chilkoti ,  Nidhi Nath ,  Wolfgang Frey

Inventor： Ashutosh Chilkoti ,  Nidhi Nath ,  Wolfgang Frey

IPC: G01N33/543

CPC classification number: B82Y30/00 ,  G01N33/54353 ,  G01N33/54373 ,  G01N33/553 ,  Y10S436/805 ,  Y10S436/817 ,  Y10S436/827

Abstract: Disclosed are sensors for use in testing biological, biochemical, chemical or environmental samples, and methods of making and using the same.

公开(公告)号：US20050255554A1

公开(公告)日：2005-11-17

申请号：US11053100

申请日：2005-02-08

Applicant: Ashutosh Chilkoti

Inventor： Ashutosh Chilkoti

IPC: C07K14/36 ,  C07K14/78 ,  C12N9/02 ,  C12N15/62 ,  C12P21/04 ,  A61K38/17 ,  C07H21/04 ,  C12N9/00 ,  C12N15/09 ,  C12P21/06

CPC classification number: C07K14/36 ,  A01K2217/05 ,  C07K14/78 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/10 ,  C07K2319/20 ,  C07K2319/35 ,  C07K2319/40 ,  C07K2319/50 ,  C12N9/0036 ,  C12N15/62

Abstract: Genetically-encodable, environmentally-responsive fusion proteins comprising ELP peptides. Such fusion proteins exhibit unique physico-chemical and functional properties that can be modulated as a function of solution environment. The invention also provides methods for purifying the FPs, which take advantage of these unique properties, including high-throughput purification methods.

Abstract translation: 包含ELP肽的可遗传编码的环境反应性融合蛋白。 这种融合蛋白表现出独特的物理化学和功能特性，可以作为溶液环境的函数进行调节。 本发明还提供了纯化FP的方法，其利用这些独特的性质，包括高通量纯化方法。